|
|
Дата |
---|
22.08.2025 |
21.08.2025 |
20.08.2025 |
19.08.2025 |
18.08.2025 |
15.08.2025 |
14.08.2025 |
13.08.2025 |
12.08.2025 |
11.08.2025 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.905
|
1.01
|
0.925
|
0.925
|
0.967
|
0.9637
|
|
|
3 304.81
|
16.00
|
0.8356
|
0.94
|
0.8801
|
0.8757
|
0.89
|
0.8757
|
|
|
551.87
|
10.00
|
0.7969
|
0.9969
|
0.86
|
0.8516
|
0.8953
|
0.8953
|
|
|
412.34
|
6.00
|
0.89
|
1.01
|
0.93
|
0.906
|
0.9498
|
0.919
|
|
|
1 495.77
|
16.00
|
0.84
|
0.97
|
0.93
|
0.89
|
0.93
|
0.91
|
|
|
3 873.73
|
29.00
|
0.9418
|
1.07
|
0.92
|
0.92
|
0.93
|
0.93
|
|
|
887.92
|
14.00
|
0.8007
|
1.00
|
0.9999
|
0.9476
|
0.9999
|
0.9476
|
|
|
313.86
|
9.00
|
0.8308
|
1.00
|
0.93
|
0.91
|
0.95
|
0.95
|
|
|
4 474.75
|
15.00
|
0.8839
|
0.986
|
0.9447
|
0.90
|
0.9447
|
0.92
|
|
|
6 404.12
|
13.00
|
0.84
|
1.00
|
0.9465
|
0.90
|
0.9465
|
0.9171
|
|
|
1 783.88
|
18.00
|
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED lamp, Ameluz-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.
In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Показать все Скрыть